000841559 001__ 841559
000841559 005__ 20210129232034.0
000841559 0247_ $$2doi$$a10.1158/1538-7445.AM2017-2496
000841559 0247_ $$2WOS$$aWOS:000442496705345
000841559 037__ $$aFZJ-2017-08597
000841559 082__ $$a610
000841559 1001_ $$0P:(DE-HGF)0$$aKoch, Katharina$$b0
000841559 245__ $$aAbstract 2496: Targeting brain tumor stem cells by interfering with choline metabolism: Evidence for an EMT-choline oncometabolic network
000841559 260__ $$aPhiladelphia, Pa.$$bAACR$$c2017
000841559 3367_ $$2DRIVER$$aarticle
000841559 3367_ $$2DataCite$$aOutput Types/Journal article
000841559 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1520840699_25957
000841559 3367_ $$2BibTeX$$aARTICLE
000841559 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000841559 3367_ $$00$$2EndNote$$aJournal Article
000841559 520__ $$aGlioblastoma (GBM) is the most lethal primary malignant brain tumor with a median survival of less than two years. High levels of therapy resistance, strong cellular invasiveness and rapid cell growth demand aggressive multimodal therapies involving resection as well as radio-chemotherapy. Recent evidence has pointed to the existence of brain tumor stem cells (BTSCs), a subpopulation of human brain tumors which is thought to be responsible for tumor dissemination, relapse and chemo resistance. BTSCs have been associated with the expression of mesenchymal features as a result of epithelial-mesenchymal transition (EMT). Using high resolution proton nuclear magnetic resonance spectroscopy (1H NMR) we compared the intracellular metabolic composition of GBM cells after induction vs. inhibition of EMT as well as under stem cell or differentiated conditions. We identified that both EMT and enrichment for stemness induces the cholinic phenotype which is characterized by high intracellular levels of phosphocholine and total choline derivatives. Furthermore, interference with choline metabolism by targeting choline kinase alpha (CHKα) reversed EMT in GBM cells as we observed reduced invasiveness, clonogenicity, and expression of EMT associated genes. Taken together, interfering with choline metabolism is a powerful strategy to suppress EMT and thus target BTSCs. Moreover, the newly identified BTSC-oncometabolic network could be used to non-invasively monitor the invasive properties of glioblastomas and the success of anti-BTSC therapy.
000841559 536__ $$0G:(DE-HGF)POF3-551$$a551 - Functional Macromolecules and Complexes (POF3-551)$$cPOF3-551$$fPOF III$$x0
000841559 7001_ $$0P:(DE-Juel1)132001$$aHartmann, Rudolf$$b1$$ufzj
000841559 7001_ $$0P:(DE-HGF)0$$aSuwala, Abigail K.$$b2
000841559 7001_ $$0P:(DE-HGF)0$$aRios, Dayana Herrera$$b3
000841559 7001_ $$0P:(DE-HGF)0$$aKahlert, Ulf D.$$b4
000841559 7001_ $$0P:(DE-HGF)0$$aMaciaczyk, Jaroslaw$$b5$$eCorresponding author
000841559 773__ $$0PERI:(DE-600)2036785-5$$a10.1158/1538-7445.AM2017-2496$$n13$$p2496$$tCancer research$$v77$$x0008-5472$$y2017
000841559 909CO $$ooai:juser.fz-juelich.de:841559$$pVDB
000841559 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132001$$aForschungszentrum Jülich$$b1$$kFZJ
000841559 9131_ $$0G:(DE-HGF)POF3-551$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vFunctional Macromolecules and Complexes$$x0
000841559 9141_ $$y2018
000841559 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000841559 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER RES : 2015
000841559 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000841559 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000841559 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000841559 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000841559 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000841559 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000841559 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000841559 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000841559 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000841559 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000841559 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000841559 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER RES : 2015
000841559 920__ $$lyes
000841559 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000841559 980__ $$ajournal
000841559 980__ $$aVDB
000841559 980__ $$aI:(DE-Juel1)ICS-6-20110106
000841559 980__ $$aUNRESTRICTED
000841559 981__ $$aI:(DE-Juel1)IBI-7-20200312